BUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;

Reuters

Sep 12, 2024

** Shares of cancer therapy developer Oncternal Therapeutics

hit record low, last down 59.32% at $1.69

** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives

** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease

** There was one death related to complications of shock at the highest dose tested with ONCT-808

** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources

** Stock down 85% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466020662"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466020662\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466020662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-12 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466020662","market":"us","top_or_hot":-1,"title":"BUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;","media":"Reuters","content":"<html><body><p>** Shares of cancer therapy developer Oncternal <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></p><p>  hit record low, last down 59.32% at $1.69</p><p>   ** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives</p><p>   ** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease</p><p>    ** There was one death related to complications of shock at the highest dose tested with ONCT-808</p><p>   ** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources</p><p>   ** Stock down 85% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-09-12 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of cancer therapy developer Oncternal <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></p><p>  hit record low, last down 59.32% at $1.69</p><p>   ** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives</p><p>   ** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease</p><p>    ** There was one death related to complications of shock at the highest dose tested with ONCT-808</p><p>   ** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources</p><p>   ** Stock down 85% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCT","symbol_name":"Oncternal Therapeutics, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2466020662","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466020662","pubTimestamp":1726150495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of cancer therapy developer Oncternal Therapeutics  hit record low, last down 59.32% at $1.69   ** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives   ** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease    ** There was one death related to complications of shock at the highest dose tested with ONCT-808   ** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources   ** Stock down 85% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONCT":"Oncternal Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Oncternal计划取消研究、探索战略替代方案，创下历史新低；","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCT":0.9},"content_text":"** Shares of cancer therapy developer Oncternal Therapeutics  hit record low, last down 59.32% at $1.69   ** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives   ** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease    ** There was one death related to complications of shock at the highest dose tested with ONCT-808   ** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources   ** Stock down 85% YTD (Reporting by Sriparna Roy in Bengaluru)((Sriparna.Roy@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}